Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. Highly effective vaccines and immunogenic compositions against HSV-2, which can be used therapeutically or prophylactically, are described.
1. A vaccine formulation comprising a pharmaceutically-acceptable carrier, a first polypeptide consisting of an amino acid sequence having at least 95% identity to SEQ ID NO: 136, and a second polypeptide comprising an amino acid sequence having at least 95% identity to any one of SEQ ID NOS: 1, 2, 4, 5, 13, 138, 139 and SEQ ID NO:4 lacking a cytoplasmic region, or an immunogenic fragment thereof.
2. The vaccine formulation of claim 1 , wherein the second polypeptide comprises an amino acid sequence having at least 95% identity to one of SEQ ID NO:4, SEQ ID NO:4 lacking a cytoplasmic region, SEQ ID NO:5, or immunogenic fragments thereof.
3. The vaccine formulation of claim 2 , further comprising a third polypeptide comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 2 or immunogenic fragments thereof.
4. The vaccine formulation of claim 2 , further comprising a third polypeptide consisting of SEQ ID NO: 138 or immunogenic fragments thereof.
5. The vaccine formulation of claim 1 , wherein the second polypeptide consists of one of SEQ ID NOS: 1, 2, 13, 138 and 139, or immunogenic fragments thereof.
6. The vaccine formulation of claim 5 , further comprising a third polypeptide consisting of SEQ ID NO:4, SEQ ID NO:4 lacking a cytoplasmic region, SEQ ID NO:5, or immunogenic fragments thereof.
7. The vaccine formulation of claim 1 , wherein the second polypeptide consists of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO: 138, or immunogenic fragments thereof.
8. A vaccine formulation comprising a pharmaceutically-acceptable carrier and a polypeptide consisting of an amino acid sequence having at least 95% identity to SEQ ID NO: 136.
9. The vaccine formulation of claim 1 , further comprising an adjuvant.
10. The vaccine formulation of claim 9 , wherein the adjuvant is one or more purified fractions of Quillaja saponins.
11. The vaccine formulation of claim 10 , wherein the adjuvant comprises saponin fraction A and saponin fraction C.
12. The vaccine formulation of claim 11 , wherein the adjuvant comprises cholesterol, phosphatidyl choline, saponin fraction A and saponin fraction C.
13. The vaccine formulation of claim 12 , wherein the adjuvant is in the form of particles.
14. The vaccine formulation of claim 13 , wherein particles comprising saponin fraction A are substantially free of saponin fraction C and particles comprising saponin fraction C are substantially free of saponin fraction A.
15. The vaccine formulation of claim 9 , wherein the vaccine formulation comprises 5-200 μg of each polypeptide and 5-200 μg of the adjuvant.
16. The vaccine formulation of claim 1 , wherein the second polypeptide further comprises a tag.
17. A method for inhibiting HSV-2 infection in a subject, comprising administering to the subject an effective amount of a vaccine formulation according to claim 1 .
18. The method of claim 17 , wherein the method inhibits HSV-2 infection in a subject after a three dose regimen.
19. The method of claim 17 , wherein the subject is a human.
20. The method of claim 17 , wherein the subject has not been previously infected with HSV-2.
21. A method for treating HSV-2 infection in a subject, comprising administering an effective amount of a vaccine formulation according to claim 1 .
22. The method of claim 21 , wherein the method inhibits onset or reduces severity of HSV-2 symptoms.
23. The method of claim 22 , wherein the method reduces the number of herpetic lesions.
24. The method of claim 23 , wherein the method reduces the number of days a subject experiences herpetic lesions.
25. The method of claim 21 , wherein the method increases the IgG titer to one or more HSV-2 antigens.
26. The method of claim 21 , wherein the method increases the T cell response to one or more HSV-2 antigens.
27. The method of claim 21 , wherein the method reduces the number of herpetic lesions at the onset of HSV-2 infection.
28. The method of claim 21 , wherein the method inhibits onset or reduces severity of HSV-2 symptoms in a subject after a three dose regimen.
29. The method of claim 21 , wherein the subject is a human.
30. The method of claim 21 , wherein the subject has not been previously infected with HSV-2.
31. The vaccine formulation of claim 1 , wherein upon administration to an asymptomatic subject infected with HSV-2, the vaccine formulation induces an immune response in the subject.
32. The method of claim 17 , wherein the subject is infected with HSV-2 and asymptomatic.
33. The method of claim 17 , wherein the subject has been exposed to HSV-2 but is seronegative.
34. The vaccine formulation of claim 1 , wherein the first polypeptide consists of the amino acid sequence of SEQ ID NO:136.
35. The vaccine formulation of claim 1 , wherein the formulation comprises a heterodimer comprising the first polypeptide.
36. The vaccine formulation of claim 8 , wherein the formulation comprises a heterodimer comprising the polypeptide.